Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.58 |
| ▸ | CA1 | P00915 | 4/20 | 0.58 |
| ▸ | CA2 | P00918 | 4/20 | 0.58 |
| ▸ | CA7 | P43166 | 4/20 | 0.58 |
| ▸ | CA9 | Q16790 | 4/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | SNCA | P37840 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7139650 | 0.96 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL254063 | 0.88 | CYP3A4 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL39875 | 0.83 | SERPINE1 (0.63) | CYP3A4KDM4ESERPINE1 | |
| SCHEMBL2787842 | 0.82 | CYP3A4 (0.54) | CA12CA1CA2CA9CYP3A4 | |
| SCHEMBL26374737 | 0.81 | SNCA (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10918370 | 0.81 | CYP3A4 (0.53) | CA12CA1CA2CA9CYP3A4 | |
| SCHEMBL31182 | 0.81 | SNCA (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16246769 | 0.81 | CYP3A4 (0.52) | CYP3A4SNCAALDH1A1HSD17B10TSHR | |
| SCHEMBL7196703 | 0.81 | CYP3A4 (0.52) | CYP3A4SNCAALDH1A1HSD17B10TSHR | |
| SCHEMBL5094573 | 0.80 | CYP3A4 (0.47) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671001-B2 | Alkaline, post plasma etch/ash residue removers and photoresist stripping compositions containing metal-halide corrosion inhibitors | MALLINCKRODT BAKER, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7435747-B2 | Guanidine and amidine derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-14 | — | — | US | disclosed |
| US-20070060490-A1 | Alkaline, post plasma etch/ash residue removers and photoresist stripping compositions containing metal-halide corrosion inhibitors | AVANTOR PERFORMANCE MATERIALS, INC. | 2007-03-15 | — | — | US | disclosed |
| EP-1345900-B1 | GUANIDINE AND AMIDINE DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-01-17 | — | — | EP | disclosed |
| EP-1692572-A2 | ALKALINE, POST PLASMA ETCH/ASH RESIDUE REMOVERS AND PHOTORESIST STRIPPING COMPOSITIONS CONTAINING METAL-HALIDE CORROSION INHIBITORS | Mallinckrodt Baker, Inc. (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20050143419-A1 | Guanidine and amidine derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-30 | — | — | US | disclosed |
| WO-2005043245-A2 | ALKALINE, POST PLASMA ETCH/ASH RESIDUE REMOVERS AND PHOTORESIST STRIPPING COMPOSITIONS CONTAINING METAL-HALIDE CORROSION INHIBITORS | MALLINCKRODT BAKER INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| CN-1479722-A | Guanidine and amidine derivatives as factor Xa inhibitors | ���ĵ�˹ҩ��¹�����˾ | 2004-03-03 | — | — | CN | disclosed |
| EP-1345900-A1 | GUANIDINE AND AMIDINE DERIVATIVES AS FACTOR XA INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2003-09-24 | — | — | EP | disclosed |
| US-20020173656-A1 | Guanidine and amidine derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-11-21 | — | — | US | disclosed |
| WO-2002046159-A1 | GUANIDINE AND AMIDINE DERIVATIVES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173656-A1 | Guanidine and amidine derivatives as factor Xa inhibitors | F5, F9, F10 | CA12 4617/4885CA1 3803/4885CA2 3113/4885 |
| US-20050143419-A1 | Guanidine and amidine derivatives as factor Xa inhibitors | F5, F10, F12 | CA12 4557/4885CA1 3854/4885CA2 3357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.